Affiliation:
1. Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences Catholic University Leuven Leuven Belgium
2. Division of Nuclear Medicine University Hospital Leuven and Nuclear Medicine and Molecular Imaging, KU Leuven Leuven Belgium
3. CuraSen Therapeutics San Carlos California USA
4. Invicro London UK
5. Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK
Abstract
AimsCerebral hypometabolism occurs years prior to a diagnosis of neurodegenerative diseases and coincides with reduced cerebral perfusion and declining noradrenergic transmission from the locus coeruleus. In pre‐clinical models, β‐adrenoceptor (β‐AR) agonists increase cerebrocortical glucose metabolism, and may have therapeutic potential for neurodegenerative diseases. This study investigated the safety and effects on regional cerebral blood flow (rCBF) of the oral, brain‐penetrant β2‐AR agonist, clenbuterol, in healthy volunteers (HV) and patients with mild cognitive impairment (MCI) or Parkinson's disease (PD).MethodsThis study evaluated the safety and effects on cerebral activity of the oral, brain‐penetrant, β2‐AR agonist clenbuterol (20–160 μg) in healthy volunteers and patients with MCI or PD. Regional CBF, which is tightly coupled to glucose metabolism, was measured by arterial spin labelling MRI in 32 subjects (25 HV and 8 MCI or PD) across five cohorts. In some cohorts, low doses of nadolol (1–5 mg), a β‐AR antagonist with minimal brain penetration, were administered with clenbuterol to control peripheral β2‐AR responses.ResultsSignificant, dose‐dependent increases in rCBF were seen in multiple brain regions, including hippocampus, amygdala and thalamus, following the administration of clenbuterol to HVs (mean changes from baseline in hippocampal rCBF of −1.7%, 7.3%, 22.9%, 28.4% 3 h after 20, 40, 80 and 160 μg clenbuterol, respectively). In patients with MCI or PD, increases in rCBF following 80 μg clenbuterol were observed both without and with 5 mg nadolol (in hippocampus, 18.6%/13.7% without/with nadolol). Clenbuterol was safe and well‐tolerated in all subjects; known side effects of β2‐agonists, including increased heart rate and tremor, were mild in intensity and were blocked by low‐dose nadolol.ConclusionsThe effects of clenbuterol on rCBF were evident both in the absence and presence of low‐dose nadolol, suggesting central nervous system (CNS) involvement. Concomitant inhibition of the peripheral effects of clenbuterol by nadolol confirms that meaningful β2‐AR antagonism in the periphery was achieved without interrupting the central effects of clenbuterol on rCBF.